[A20-44] Apremilast (Behçet’s disease) - Benefit assessment according to §35a Social Code Book V
Last updated 17.08.2020
Commission awarded on 06.05.2020 by the Federal Joint Committee (G-BA).
Immune system and infections
Adults with Behçet’s disease and oral ulcers who are candidates for systemic therapy
Added benefit not proven due to lack of suitable comparative data
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.